Zydus Cadila has received the final approval from the USFDA to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD-Mycolog-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.

The group now has 226 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 2.6, or 0.72%, to trade at Rs 357.75. The total volume of shares traded was 28,118 at the BSE (1.32 p.m., Monday).